IMIST


Vue normale Vue MARC vue ISBD

Gene therapy of cancer :

Mention d'édition :2nd ed. Détails physiques : 1 online resource (xix, 534 pages) : illustrations (some color) ISBN :9780124375512; 0124375510; 9780080491363 (electronic bk.); 0080491367 (electronic bk.).
Tags de cette bibliothèque : Pas de tags pour ce titre. Connectez-vous pour ajouter des tags.
    Évaluation moyenne : 0.0 (0 votes)
Type de document Site actuel Cote Statut Date de retour prévue Code à barres Réservations
Livre La bibliothèque des Sciences Médicales et Pharmaceutiques
616.994 LAT (Parcourir l'étagère) Disponible 0000000009478
Total des réservations: 0

The Second Edition of Gene Therapy of Cancer provides crucial updates on the basic science and ongoing research in this field, examining the state of the art technology in gene therapy and its therapeutic applications to the treatment of cancer. The clinical chapters are improved to include new areas of research and more successful trials. Chapters emphasize the scientific basis of gene therapy using immune, oncogene, antisense, pro-drug activating, and drug resistance gene targets, while other chapters discuss therapeutic approaches and clinical applications. This book is a valuable reference for anyone needing to stay abreast of the latest advances in gene therapy treatment for cancer. Key Features * Provides in-depth description of targeted systems and treatment strategies * Explains the underlying cancer biology necessary for understanding a given therapeutic approach * Extensively covers immune therapeutics of vaccines, cytokines, and peptide-induced responses * Presents translational focus with emphasis on requirements for clinical implementation * Incorporates detailed illustrations of vectors and therapeutic approaches ideal for classroom presentations and general reference.

Includes bibliographical references and index.

Ch. 1. Retroviral vector design for cancer gene therapy -- Ch. 2. Noninfectious gene transfer and expression systems for cancer gene therapy -- Ch. 3. Parvovirus vectors for the gene therapy of cancer -- Ch. 4. Antibody-targeted gene therapy -- Ch. 5. Ribozymes in cancer gene therapy -- Ch. 6. The advent of lentiviral vectors: prospects for cancer therapy -- Ch. 7. Immunologic targets for the gene therapy of cancer -- Ch. 8. Development of epitope-specific immunotherapies for human malignancies and premalignant lesions expressing mutated ras genes -- Ch. 9. Introduction to dendritic cells -- Ch. 10. DNA and dendritic cell-based genetic immunization against cancer -- Ch. 11. RNA-transfected dendritic cells as immunogens -- Ch. 12. In Situ immune modulation using recombinant vaccinia virus vectors: preclinical studies to clinical implementation -- Ch. 13. The use of particle-mediated gene transfer for immunotherapy of cancer -- Ch. 14. Applications of gene transfer in the adoptive immunotherapy of cancer -- Ch. 15. Update on the use of genetically modified hematopoietic stem cells for cancer therapy -- Ch. 16. Clinical applications of tumor-suppressor gene therapy -- Ch. 17. Cancer gene therapy with tumor suppressor genes involved in cell-cycle control.

Ch. 18. Cancer gene therapy with the p53 tumor suppressor gene -- Ch. 19. Antisense downregulation of the apoptosis-related Bcl-2 and Bcl-xl proteins: a new approach to cancer therapy -- Ch. 20. Gene therapy for chronic myelogenous leukemia -- Ch. 21. Transfer of drug-resistance genes into hematopoietic progenitors -- Ch. 22. Multidrug-resistance gene therapy in hematopoietic cell transplantation -- Ch. 23. Development and application of an engineered dihydrofolate reductase and cytidine-deaminase-based fusion genes in myeloprotection-based gene therapy strategies -- Ch. 24. Protection from antifolate toxicity by expression of drug-resistant dihydrofolate reductase -- Ch. 25. A genomic approach to the treatment of breast cancer -- Ch. 26. Antiangiogenic gene therapy -- Ch. 27. VEGF-targeted antiangiogenic gene therapy -- Ch. 28. Strategies for combining gene therapy with ionizing radiation to improve antitumor efficacy -- Ch. 29. Virotherapy with replication-selective oncolytic adenoviruses: a novel therapeutic platform for cancer -- Ch. 30. E1A cancer gene therapy -- Ch. 31. Preemptive and therapeutic uses of suicide genes for cancer and leukemia -- Ch. 32. Treatment of mesothelioma using adenoviral-mediated delivery of herpes simplex virus thymidline kinase gene in combination with ganciclovir -- Ch. 33. The use of suicide gene therapy for the treatment of malignancies of the brain -- Ch. 34. Case study of combined gene and radiation therapy as an approach in the treatment of cancer.

Il n'y a pas de commentaire pour ce document.

pour proposer un commentaire.
© Tous droits résérvés IMIST/CNRST
Angle Av. Allal Al Fassi et Av. des FAR, Hay Ryad, BP 8027, 10102 Rabat, Maroc
Tél:(+212) 05 37.56.98.00
CNRST / IMIST

Propulsé par Koha